Component
Recombinant ERp57 preparation in the 2018 RA study
Recombinant ERp57 preparation in the 2018 RA study
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
What acts on it
RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.
Experimental context and source evidence
- evidence_access
- Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
- experimental_contrast
- {"intervention": "RA concentration series", "comparator": "Vehicle", "endpoint": "RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; recorded from source.
- experimental_model
- 2018 DTT-containing turbidity assay, 84 min; recombinant construct species not stated explicitly in Methods.
- interpretation_status
- Recorded from source with stated access limits; ungraded, not independent replication.
- limitations
- Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.
- nutrient_topic
- Rosmarinic acid collection; exact intervention and molecular form govern interpretation. · Rosmarinic acid
- plain_language
- RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar.
- primary_references
- Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen <i>(Salvia miltiorrhiza)</i>. | https://pubmed.ncbi.nlm.nih.gov/29849736/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5941821/ | https://doi.org/10.1155/2018/9387568
- source_locator
- Reviewed reference ra-erp57-assay; Docking contacts are predictions. Enzyme inhibition plus platelet inhibition does not alone prove ERp57 mediates the platelet effect.
Rosmarinic acid: detailed mechanisms of action (reviewed 10 October 2026) · lines 562–568
AI-assisted original curation of primary studies; claim-local access and experimental limitations stated. Includes original-draft correction history. No independent replication claimed. · supports · 2018 DTT-containing turbidity assay, 84 min; recombinant construct species not stated explicitly in Methods. · Recorded from source · Recorded from source
### ra-erp57-assay RA inhibited recombinant ERp57-dependent insulin reduction, IC50 176.82 micromolar. Docking contacts are predictions. Enzyme inhibition plus platelet inhibition does not alone prove ERp57 mediates the platelet effect. Model and exposure: 2018 DTT-containing turbidity assay, 84 min; recombinant construct species not stated explicitly in Methods. Limitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation. Reference: Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen <i>(Salvia miltiorrhiza)</i>. | 2018 | https://pubmed.ncbi.nlm.nih.gov/29849736/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC5941821/ | https://doi.org/10.1155/2018/9387568 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.